tacrolimus has been researched along with Uterine-Cervical-Dysplasia* in 3 studies
1 trial(s) available for tacrolimus and Uterine-Cervical-Dysplasia
Article | Year |
---|---|
De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin.
Although conventional immunosuppression after liver transplantation consists of cyclosporine A (CsA), steroids, and azathioprine, recently introduced protocols entail CsA-based quadruple induction protocols or tacrolimus-based combinations. These protocols aim to reduce the rejection rate and the considerable morbidity related to the side effects of additional immunosuppressive treatment, but have not yet been analyzed regarding their long term de novo neoplastic risk.. From September 1988 to May 1994, 500 liver transplantations were performed in 458 patients. The median follow-up was 50 months (range, 0.3-97 months) for all patients. Conventional triple therapy was implemented in 25 patients, CsA-based quadruple induction therapy using an antilymphocyte globulin preparation (ATG) in 190 patients, an interleukin-2 receptor antibody (BT563) in 141 patients, and tacrolimus-based dual or triple immunosuppression in 102 patients. The different protocols were evaluated in four randomized and two nonrandomized prospective trials.. De novo neoplasias were detected in 33 patients (7.2%) and were comprised of lymphomas (n = 7), skin malignancies (n = 8 lesions in 7 patients), intraepithelial neoplasias of the cervix uteri (n = 7), breast carcinoma (n = 3), lung carcinoma (n = 3), and other malignancies (n = 6). The incidence of de novo neoplasias did not differ in the different trial arms. Only a positive T-crossmatch and a low CD4+/CD8+ ratio in patients receiving CsA-based immunosuppression demonstrated a significant correlation with the development of a de novo tumor in a multivariant logistic regression analysis.. The development of de novo neoplastic diseases after liver transplantation with the use of CsA-based quadruple induction protocols or tacrolimus-based regimens for immunosuppresion was assessed over the long term. Recently introduced immunosuppressive protocols did not alter the posttransplant de novo tumor rate. Patients with a low CD4+/CD8+ ratio during CsA-based therapy or a positive T-crossmatch were identified to be at an increased risk for the development of a de novo malignancy. Topics: Antibodies, Monoclonal; Antilymphocyte Serum; Clinical Trials as Topic; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Liver Transplantation; Lymphoma; Neoplasms, Second Primary; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Interleukin-2; Skin Neoplasms; Tacrolimus; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms | 1997 |
2 other study(ies) available for tacrolimus and Uterine-Cervical-Dysplasia
Article | Year |
---|---|
[Occurrence of suspicious changes in cervix cytology in women after liver transplantation].
After transplantation the necessary immunosuppressive therapy predisposes to the development of de novo cancers. From January 1989 to April 1994 we collected PAR smears of 98 women before and repeatedly after liver transplantation. After surgery all women received as immunosuppressive agents either Cyclosporin A or FK 506 as long-term medication. In seven patients (8.5%) who had a normal cervical cytology before transplantation a suspicious PAP smear was found on average 11 months after transplantation. In five cases a histological verification (exploratory excision, coning of the cervix) was made. In two cases we found a CIN III. Possible causes for the higher incidence of dysplasia of the cervix observed in the transplant patients are discussed. Similar to kidney transplant recipients female liver transplant recipients are at higher risk of developing cervical dysplasias and neoplasias. Accelerated development of malignancy seems likely. The influence on the cervical cells of both immunosuppressive drugs Cyclosporin A and FK 506 seems to be of a similar nature. Recommendations for the gynaecological care of female liver transplant recipients treated with immunosuppressive therapy are given. Topics: Adult; Aged; Cervix Uteri; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Liver Transplantation; Middle Aged; Neoplasm Staging; Papanicolaou Test; Risk Factors; Tacrolimus; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaginal Smears | 1995 |
[Changes in cervix cytology in women with liver transplants treated with immunosuppressive therapy].
During the time 1989 to 1992 we collected PAP smears of 58 women before and several times after a liver transplantation. Five of the patients (= 8.6%) showed a suspicious PAP smear, although pre-transplantation they had a normal cervical cytology. Histological one woman even had a higher grade dysplasia. 30 women received FK 506 after the liver transplantation, 28 patients Cyclosporin A as long-term medication. Likewise kidney and liver transplanted women have a higher risk to be affected by a cervical neoplasia. A acceleration of malignant growth seems to be likely. The influence on the cervical cells of both immunosuppressive drugs Cyclosporin A (Sandimmun) and FK 506 seem to be similar. It should be recommended to perform a close-meshed cervical cytology control when following -up the female liver transplant recipients. Topics: Adolescent; Adult; Aged; Cervix Uteri; Cyclosporine; Female; Follow-Up Studies; Humans; Liver Transplantation; Middle Aged; Neoplasm Staging; Papanicolaou Test; Postoperative Complications; Precancerous Conditions; Risk Factors; Smoking; Tacrolimus; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaginal Smears | 1993 |